Supernus Pharma Q3 revenue rises, partly helped by Sage acquisition

Supernus Pharmaceuticals

04/11/2025 21:34

Overview

Supernus Q3 2025 total rev rises 9% yr/yr, driven by growth products

Company completed acquisition of Sage Therapeutics, contributing to collaboration revenue

Operating loss in Q3 due to acquisition-related costs

Outlook

Supernus raises full-year 2025 revenue guidance to $685 mln - $705 mln

Company updates 2025 operating loss guidance to $(65) mln - $(75) mln

Supernus expects 2025 adjusted operating earnings of $125 mln - $145 mln

Result Drivers

GROWTH PRODUCTS - Combined revenues from Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO increased 52% to $149.2 mln, driving overall revenue growth

ONAPGO LAUNCH - ONAPGO generated $6.8 mln in sales in its first full quarter post-launch, but supply constraints are limiting new patient starts

SAGE ACQUISITION - Acquisition of Sage Therapeutics contributed $20.2 mln in collaboration revenue from ZURZUVAE

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Sales
$168.50 mln
Q3 Adjusted Revenue
$170 mln
Q3 EPS
-$0.80
Q3 Operating Earnings
-$60.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc is $61.50, about 9.4% above its November 3 closing price of $55.70

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nGNX243F1V

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)